Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein–ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR

References

• Abagyan, R., Totrov, M., & Kuznetsov, D. (1994). ICM – A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. Journal of Computational Chemistry, 15(5), 488–506. doi:10.1002/jcc.540150503
   Web of Science ®Google Scholar
• Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W., & Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Research, 25(17), 3389–3402. [PMID: 9254694].
   PubMed Web of Science ®Google Scholar
• Andrade, C. H., Salum, L. B., Pasqualoto, K. F. M., Ferreira, E. I., & Andricopulo, A. D. (2008). Three-dimensional quantitative structure-activity relationships for a large series of potent antitubercular agents. Letters in Drug Design & Discovery, 5, 377–387.
   Web of Science ®Google Scholar
• Bartenschlager, R., Ahlborn-Laake, L., Mous, J., & Jacobsen, H. (1994). Kinetic and structural analyses of hepatitis C virus polyprotein processing. Journal of Virology, 68(8), 5045–5055.
   PubMed Web of Science ®Google Scholar
• Baxter, J. (1981). Local optima avoidance in depot location. Journal of the Operational Research Society, 32(9), 815–819. doi:10.1057/jors.1981.159
   Web of Science ®Google Scholar
• Blum, A. R. C., Blesa, M., & Sampels, M. (Eds.). (2008). Hybrid metaheuristics: An emerging approach to optimization. Berlin, Heidelberg: Springer-Verlag.
   Google Scholar
• Bressanelli, S., Tomei, L., Rey, F. A., & De Francesco, R. (2002). Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. Journal of Virology, 76(7), 3482–3492. doi:10.1128/JVI.76.7.3482-3492.2002
   PubMed Web of Science ®Google Scholar
• Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., … Woods, R. J. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26(16), 1668–1688. doi:10.1002/jcc.20290
   PubMed Web of Science ®Google Scholar
• Clark, A., Labute, P., & Santavy, M. (2006). 2D structure depiction. Journal of Chemical Information and Modeling, 46(3), 1107–1123. doi:10.1021/ci050550m
   PubMed Web of Science ®Google Scholar
• Colovos, C., & Yeates, T. O. (1993). Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Science, 2(9), 1511–1519. doi:10.1002/pro.5560020916
   PubMed Web of Science ®Google Scholar
• Cramer, R. D., Patterson, D. E., & Bunce, J. D. (1988). Comparative molecular field analysis (CoMFA) – 1: Effect of shape on binding of steroids to carrier proteins. Journal of the American Chemical Society, 110(18), 5959–5967. doi:10.1021/ja00226a005
   PubMed Web of Science ®Google Scholar
• Deng, Z., Chuaqui, C., & Singh, J. (2004). Structural interaction fingerprint (SIFt): A novel method for analyzing three dimensional protein − ligand binding interactions. Journal of Medicinal Chemistry, 47(2), 337–344. doi:10.1021/jm030331x
   PubMed Web of Science ®Google Scholar
• Deschenes, A., & Sourial, E. (2007). Ligand scaffold replacement using MOE pharmacophore tools. JCCG.
   Google Scholar
• Doublie, S., Tabor, S., Long, A. M., Richardson, C. C., & Ellenberger, T. (1998). Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 A resolution. Nature, 391, 251–258. doi:10.1038/34593
   PubMed Web of Science ®Google Scholar
• El-Hasab, M. A. E.-M., El-Bastawissy, E. E., & El-Moselhy, T. F. (2017). Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein–ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation. Journal of Biomolecular Structure and Dynamics, 36, 1713–1727. doi:10.1080/07391102.2017.1332689
   PubMed Web of Science ®Google Scholar
• Elumalai, P., Liu, H. L., Zhou, Z. L., Zhao, J. H., Chen, W., Chuang, C. K., & Ho, Y. (2012). Ligand and structure-based pharmacophore modeling for the discovery of potential human HNMT inhibitors. Letters in Drug Design & Discovery, 9(1). doi:10.2174/157018012798192955
   Web of Science ®Google Scholar
• Fei, J., Zhou, L., Liu, T., & Tang, X. (2013). Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors. International Journal of Medical Sciences, 10(3), 265–275. doi:10.7150/ijms.5344
   PubMed Web of Science ®Google Scholar
• Grimshaw, S. (2010). Scaffold replacement in MOE. JCCG.
   Google Scholar
• Guan, Y., Sun, H., Li, Y., Pan, P., Li, D., & Hou, T. (2014). The competitive binding between inhibitors and substrates of HCV NS3/4A protease: A general mechanism of drug resistance. Antiviral Research, 103, 60–70. doi:10.1016/j.antiviral.2014.01.010
   PubMed Web of Science ®Google Scholar
• Gunner, O. F., & Henry, D. R. (2000). Pharmacophore perception, development, and use in drug design. In O. F. Gunner (Ed.), Metric for analyzing hit lists and pharmacophore (pp. 193–231). La Jolla: International University Line, Biotechnology Series.
   Google Scholar
• Huiding, X., Kaixiong, Q., & Xiaoguang, X. (2014). 3D QSAR studies, pharmacophore modeling and virtual screening on a series of steroidal aromatase inhibitors. International Journal of Molecular Sciences, 15, 20927–20947.
   PubMed Web of Science ®Google Scholar
• Joyce, C. M., & Steitz, T. A. (1995). Polymerase structures and function: Variations on a theme? Journal of Bacteriology, 177(22), 6321–6329. doi:10.1128/jb.177.22.6321-6329.1995
   PubMed Web of Science ®Google Scholar
• Khattab, M. A., Ferenci, P., Hadziyannis, S. J., Colombo, M., Manns, M. P., Almasio, P. L., … Lee, S. S. (2011). Management of hepatitis C virus genotype 4: Recommendations of an international expert panel. Journal of Hepatology, 54(6), 1250–1262. doi:10.1016/j.jhep.2010.11.016
   PubMed Web of Science ®Google Scholar
• Krekulová, L., Řehák, V., & Riley, L. W. (2006). Structure and functions of hepatitis C virus proteins: 15 years after. Folia Microbiologica, 51(6), 665–680. doi:10.1007/BF02931636
   PubMed Web of Science ®Google Scholar
• Labonte, P., Axelrod, V., Agarwal, A., Aulabaugh, A., Amin, A., & Mak, P. (2002). Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure based site-directed mutagenesis. Journal of Biological Chemistry, 277, 38838–38846. doi:10.1074/jbc.M204657200
   PubMed Web of Science ®Google Scholar
• Labute, P., Williams, C., Feher, M., Sourial, E., & Schmidt, J. M. (2001). Flexible alignment of small molecules. Journal of Medicinal Chemistry, 44(10), 1483–1490. doi:10.1021/jm0002634
   PubMed Web of Science ®Google Scholar
• Lang, K., & Weiner, D. B. (2008). Immunotherapy for HCV infection: Next steps. Expert Review of Vaccines, 7(7), 915–923. doi:10.1586/14760584.7.7.915
   PubMed Web of Science ®Google Scholar
• Li, L.-S., Zhou, Y., Murphy, D. E., Stankovic, N., Zhao, J., Dragovich, P. S., … Kissinger, C. R. (2008). Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Bioorganic & Medicinal Chemistry Letters, 18(11), 3446–3455. doi:10.1016/j.bmcl.2008.02.072
   PubMed Web of Science ®Google Scholar
• Lidenbach, B. D., Thiel, H. J., & Rice, C. M. (2007). Flaviviridae: The viruses and their replication. Fields, 1, 1101–1152.
   Google Scholar
• Lovell, S. C., Davis, I. W., Arendall Iii, W. B., de Bakker, P. I. W., Word, J. M., Prisant, M. G. … Richardson, D. C. (2002). Structure validation by C alpha geometry: Phi, psi and C beta deviation. Proteins: Structure, Function, and Bioinformatics, 50, 437–450. doi:10.1002/prot.10286
   Web of Science ®Google Scholar
• Lüthy, R., Bowie, J. U., & Eisenberg, D. (1992). Assessment of protein models with three-dimensional profiles. Nature, 356(6364), 83–85. doi:10.1038/356083a0
   PubMed Web of Science ®Google Scholar
• Meeprasert, A., Hannongbua, S., & Rungrotmongkol, T. (2014). Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus. Journal of Chemical Information and Modeling, 54(4), 1208–1217. doi:10.1021/ci400605a
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). (2014). Montreal: Chemical computing group. Retrieved from https://www.chemcomp.com.
   Google Scholar
• Özen, A., Sherman, W., & Schiffer, C. A. (2013). Improving the resistance profile of hepatitis C NS3/4A inhibitors: Dynamic substrate envelope guided design. Journal of Chemical Theory and Computation, 9(12), 5693–5705. doi:10.1021/ct400603p
   PubMed Web of Science ®Google Scholar
• Pawlotsky, J. M., Chevaliez, S., & McHutchison, J. G. (2007). The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology, 132(5), 1979–1998. doi:10.1053/j.gastro.2007.03.116
   PubMed Web of Science ®Google Scholar
• Scheel, T. K. H., & Rice, C. M. (2013). Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine, 19(7), 837–849. doi:10.1038/nm.3248
   PubMed Web of Science ®Google Scholar
• Streiner, D. L., & Cairney, J. (2007). What’s under the ROC? An introduction to receiver operating characteristics curves. The Canadian Journal of Psychiatry, 52(2), 121–128. doi:10.1177/070674370705200210
   PubMed Web of Science ®Google Scholar
• Sybyl 7.0. (2003). Sybyl 7.0. St. Louis, MO: Sybyl, Tripos Inc. Retrieved from http://www.tripos.com.
   Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. Journal of Computational Chemistry, 31, 455–461. doi:10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Truchon, J. F., & Bayly, C. I. (2007). Evaluating virtual screening methods: Good and bad metrics for the “early recognition” problem. Journal of Chemical Information and Modeling, 47(2), 488–508. doi:10.1021/ci600426e
   PubMed Web of Science ®Google Scholar
• Wei, Y., Li, J., Qing, J., Huang, M., Wu, M., Gao, F., … Lin, J. (2016). Discovery of novel hepatitis C virus NS5B polymerase inhibitors by combining random forest, multiple e-pharmacophore modeling and docking. PLoS One, 11(2), e0148181. doi:10.1371/journal.pone.0148181
   PubMed Web of Science ®Google Scholar
• Xue, W., Ban, Y., Liu, H., & Yao, X. (2014). Computational Study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. Journal of Chemical Information and Modeling, 54(2), 621–633. doi:10.1021/ci400060j
   PubMed Web of Science ®Google Scholar
• Xue, W., Pan, D., Yang, Y., Liu, H., & Yao, X. (2012). Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Research, 93(1), 126–137. doi:10.1016/j.antiviral.2011.11.007
   PubMed Web of Science ®Google Scholar